Tag

Metformin

All articles tagged with #metformin

health12 days ago•7 min saved

Yale Study Identifies Metformin and Semaglutide as Top Anti-Aging Interventions

A Yale University study published in Nature Medicine analyzes 51 human trials to determine which interventions actually lower biological age. The research confirms that lifestyle changes and specific prescription drugs, notably metformin and semaglutide, significantly reduce epigenetic age markers. In contrast, over-the-counter supplements and certain medical procedures showed minimal impact. While these biomarker shifts suggest a slowing of biological aging, researchers caution that a younger clock reading does not yet guarantee longer life or reduced disease risk.

via scitechdaily.com|

#anti-aging #biological-age #epigenetics

science1 month ago•7 min saved

Metformin: The Diabetes Pill That Could Slow Healthy Aging

Scientists review metformin, a first-line diabetes drug, and its potential to slow aging by activating AMPK, inhibiting the mTOR pathway, boosting autophagy, reducing oxidative stress, and possibly driving epigenetic and gut microbiome changes; while animal studies and some human data hint at slower biological aging, there is no conclusive evidence in non-diabetic people yet, and large randomized trials like the Targeting Aging with Metformin (TAME) are needed to confirm any longevity benefits.

via ScienceAlert|

#aging #ampk #epigenetics

science1 month ago•11 min saved

Pills to Slow Aging Move From Lab to Clinic

A growing wave of anti-ageing therapies—metformin, senolytics, rapamycin and others—may slow aging and extend healthy years, with big trials like TAME aiming to treat ageing as a condition; while animal studies look promising, human trials are long, costly, and hampered by regulatory and funding hurdles.

via BBC Science Focus Magazine|

#aging #anti-ageing #healthspan

medicine-and-drugs1 month ago•138 min saved

Metformin’s core mechanism revealed: gut mitochondria drive its glucose-lowering effect

A Nature Metabolism study shows metformin lowers blood sugar primarily by inhibiting mitochondrial complex I in intestinal cells, causing those cells to burn more glucose via glycolysis. Liver-level action is less likely since liver concentrations of metformin are low. In mice engineered with a backup intestinal enzyme, the drug’s glucose-lowering effect dropped about 80%, suggesting intestinal complex I inhibition as the main acute mechanism, though researchers caution about translating findings to humans and acknowledge additional targets may exist.

via Live Science|

#complex-i #diabetes #intestines

health1 month ago•2 min saved

Metformin for granuloma annulare lacks proof, while a practical delirium-prevention plan guides care

The column explains that using metformin to treat granuloma annulare has no proven benefit yet, despite a 2026 study proposing possible mechanisms; while metformin is low-risk, it isn’t recommended without solid evidence, with standard dermatologic options including steroids, UV therapy, and, in severe cases, medicines like methotrexate or hydroxychloroquine, and emerging JAK inhibitors. The piece also outlines a comprehensive delirium-prevention plan for older patients after planned procedures, emphasizing family involvement, maintaining orientation with glasses/hearing aids and a clock, familiar objects, keeping the room well-lit during the day and dark at night, encouraging mobility, avoiding restraints, safe pain management, adequate nutrition and hydration, and careful medical monitoring to minimize delirium risk.

via The Detroit News|

#delirium #dermatology #geriatric-care

science2 months ago•6 min saved

Metformin’s Brain Link: New Pathway Behind a 60-Year-Old Diabetes Drug

A Science Advances study in mice shows metformin lowers glucose via brain Rap1 signaling in the ventromedial hypothalamus, not just liver or gut; deleting Rap1 in this brain region abolishes metformin’s effect, while direct brain administration also lowers glucose, suggesting brain-targeted mechanisms could unlock new diabetes therapies and possibly aging benefits.

via ScienceAlert|

#brain #diabetes #hypothalamus

health2 months ago•6 min saved

Two Drugs Show Early Promise in Preventing Long COVID

Two randomized trials suggest Paxlovid, started during acute SARS-CoV-2 infection, reduced the risk of developing long COVID by about 40% at three months, while metformin cut the risk of physician-diagnosed long COVID at six months by roughly half. Experts are cautiously optimistic, but definitions and generalizability vary, and more data are needed to confirm efficacy across diverse populations.

via Nature|

#health #long-covid #metformin

science2 months ago•13 min saved

Metformin’s Brain Action Unveiled: Lowering Blood Sugar via RAP1 in the Hypothalamus

Scientists have found that metformin not only acts in the liver and gut but also operates in the brain, where it suppresses the RAP1 protein in a hypothalamic region to activate glucose-lowering neurons, potentially enabling brain-targeted diabetes therapies at very low doses.

via Daily Kos|

#brain #glucose #hypothalamus

health-and-medicine2 months ago•6 min saved

Metformin's brain action unveiled: Rap1 in the hypothalamus lowers blood sugar

Researchers find metformin lowers blood sugar by acting in the brain, specifically by suppressing Rap1 in the ventromedial hypothalamus to activate SF1 neurons. These effects occur at tiny brain doses, suggesting a brain pathway adds to the drug’s known liver and gut actions and could inspire new diabetes therapies and broadened understanding of metformin’s brain benefits.

via ScienceDaily|

#diabetes #health-and-medicine #metformin

health3 months ago•16 min saved

Metformin and cancer: no broad benefit, only niche signals

A review of recent evidence shows metformin does not provide broad cancer prevention or survival benefits. Large trials (MAST in low‑risk prostate cancer; STAMPEDE) and meta-analyses report no overall improvement in progression-free or overall survival, though some small studies hint at preventive effects in select high‑risk precancerous conditions. Observational links are likely biased, and metformin may even blunt exercise‑related longevity gains. The takeaway: metformin is not a universal cancer solution; any benefit is likely limited to poorly defined, narrow contexts that require rigorous, targeted trials.

via Peter Attia MD|

#active-surveillance #cancer #health

health3 months ago•24 min saved

Healthy lifestyle outpaces metformin in long-term multimorbidity prevention

New analysis of the Diabetes Prevention Program (DPP) and its 21-year follow-up (DPPOS) found that a lifestyle intervention—low-fat, low-calorie diet plus at least 150 minutes of weekly activity—was more effective at reducing multimorbidity over two decades than metformin, which performed no better than placebo; among Medicare participants, 82% in the lifestyle group developed multiple chronic conditions versus 85% on metformin and 87% on placebo.

via New York Post|

#diabetes #diabetes-prevention-program #health

science4 months ago•5 min saved

Metformin May Boost Lifespan for Older Women, Study Suggests

A long-term, observational study of 438 postmenopausal women with type 2 diabetes found that those who started metformin had about a 30% lower risk of dying before age 90 compared with those starting a sulfonylurea. The researchers caution that the design cannot prove causation, with no placebo group and limited generalizability to men or younger people, but the roughly 14–15 years of follow-up adds evidence to metformin’s potential anti-aging effects and the geroscience hypothesis, warranting randomized trials.

via ScienceAlert|

#aging #diabetes #longevity

science4 months ago•7 min saved

Metformin’s Hidden Target: The Gut Takes Center Stage

New Northwestern University research in mice shows metformin mainly acts in the intestine, lowering blood sugar by reducing mitochondrial activity in gut cells and prompting them to burn more glucose, challenging the idea that the liver is the primary target. Published in Nature Metabolism, the study links berberine to a similar gut pathway and uses engineered mice to show that blocking mitochondrial complex I in the gut is central to metformin’s effect, with implications for gut-targeted diabetes therapies.

via SciTechDaily|

#diabetes #gut #intestine

science5 months ago•72 min saved

Gut-Targeted Complex I Blockade Reveals Metformin’s Glucose-Lowering Mechanism

A Nature Metabolism study shows metformin lowers glucose by acutely inhibiting mitochondrial complex I specifically in intestinal epithelium, reducing citrulline production and boosting GDF15, thereby reprogramming the gut into a glucose sink that takes up glucose and converts it to lactate; phenformin and berberine act via the same intestine-specific Complex I mechanism, and the effect depends on short-term bolus exposure rather than chronic dosing.

via Nature|

#citrulline #gdf15 #intestine

science5 months ago•9 min saved

Metformin targets gut mitochondria to boost glycemic control

New metabolomic and mouse studies show metformin lowers blood glucose by selectively inhibiting mitochondrial complex I in the intestinal epithelium, increasing intestinal glucose use and improving postprandial glycemic control, with raised levels of GDF15 and N-lactoyl-phenylalanine linked to systemic glucose regulation.

via Nature|

#glycemic-control #intestine #metformin